Citi analyst Yigal Nochomovitz lowered the firm’s price target on Candel Therapeutics (CADL) to $24 from $25 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Advances Cancer Therapies with Strong Q3
- Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year
- Candel Therapeutics announces it will deliver three presentations at SITC
- Candel initiated with an Overweight at Stephens on differentiated pipeline
- Candel Therapeutics initiated with an Overweight at Stephens